Aarti Drugs Limited, a diversified pharmaceutical company based in Mumbai, announced its audited financial results for the fourth quarter and financial year ending 31st March 2026. The company reported a consolidated revenue of ₹721.1 crore for Q4 FY26, marking a 6% year-on-year increase from ₹678.6 crore in Q4 FY25 and a 20% quarter-on-quarter rise from ₹602.9 crore in Q3 FY26.
The company’s earnings before interest, taxes, depreciation, and amortisation (EBITDA) for Q4 FY26 stood at ₹96.6 crore, reflecting a flat year-on-year performance compared to ₹95.2 crore in Q4 FY25. However, this represented a significant 72% increase from ₹56.3 crore in Q3 FY26. The EBITDA margin for the quarter was 13.4%, a slight decrease of 60 basis points year-on-year.
Profit after tax (PAT) for the quarter was ₹55.3 crore, a 12% decline from ₹62.8 crore in Q4 FY25, but a 36% increase quarter-on-quarter from ₹40.5 crore in Q3 FY26. The PAT margin for Q4 FY26 was 7.7%.
For the full financial year FY26, Aarti Drugs reported a revenue of ₹2,567.7 crore, a 7% increase from ₹2,403.4 crore in FY25. The EBITDA for FY26 was ₹311.6 crore, up 3% from ₹303.5 crore in the previous year, with an EBITDA margin of 12.1%. The PAT for FY26 was ₹194.9 crore, a 16% increase from ₹168.2 crore in FY25, translating to a PAT margin of 7.6%.
Segment-wise, the Active Pharmaceutical Ingredients (API) business contributed ₹551.0 crore to Q4 FY26 revenue, showing no year-on-year growth but a 21% increase quarter-on-quarter. The Formulations segment saw a 42% year-on-year increase in revenue to ₹92.0 crore, while Specialty Chemicals revenue rose 46% year-on-year to ₹56.8 crore.
Standalone business highlights for Q4 FY26 included a revenue of ₹631.7 crore, with 63% of this coming from the domestic market and 37% from exports. The company’s domestic revenue grew 7% year-on-year, while export revenue declined by 7%.
Mr. Adhish Patil, CFO & COO of Aarti Drugs, commented on the results, highlighting the company’s strong sequential recovery in Q4 FY26 despite macroeconomic challenges and pricing pressures in certain API segments. He noted that the company’s Sayakha facility achieved a milestone run-rate of approximately 1,000 tonnes per month in March 2026, contributing to the improved performance.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).